Diabetes and Parkinson disease
A sweet spot?
Citation Manager Formats

There are many superficial similarities between diabetes mellitus (DM) and Parkinson disease (PD). In both cases, clinical manifestations are primarily attributable to the decrement and then absence of a biological product (insulin and dopamine) with diminution and ultimately substantial or near-complete loss of cells in specialized tissue that produce the agent. The diseases affect multiple organ systems and can be treated by agonists and by replacement of the agent. Other options include stimulators, tissue transplants, and pumps. But deep down, there are biologically plausible cellular mechanisms that intertwine both of these conditions. Insulin receptors are relatively plentiful in substantia nigra neurons,1 and hyperglycemia suppresses substantia nigra dopaminergic neuronal firing as well as decreases dopamine turnover. Attention has increasingly focused on mitochondria as a link between DM and PD. Insulin resistance has been associated with mitochondrial dysfunction, while MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine), a toxin that caused numerous cases of parkinsonism, leads to mitochondrial dysfunction. Insulin resistance is associated with decreased genetic expression of peroxisome proliferator-activated receptor gamma, coactivator 1 alpha (PGC1 Alpha), a key regulator of mitochondrial genesis and functioning, with resultant organelle destruction (mitophagy), as well as increased oxidative stress and toxic mitochondrial mutations. Evidence suggests there may be diminished expression of PGC1 Alpha genes in PD as well.2
- © 2018 American Academy of Neurology
AAN Members: Sign in with your AAN member credentials (e-mail or 6-digit Member ID number)
Non-AAN Member subscribers: Sign in with subscriber credentials
Log in using your username and password
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00.
Disputes & Debates: Rapid online correspondence
NOTE: All contributors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.
- Stay timely. Submit only on articles published within the last 8 weeks.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- 200 words maximum.
- 5 references maximum. Reference 1 must be the article on which you are commenting.
- 5 authors maximum. Exception: replies can include all original authors of the article.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Related Articles
- No related articles found.